Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.
Antibodies, Monoclonal
/ immunology
Antibody Formation
Biological Products
/ immunology
Biomarkers
/ metabolism
Cells, Cultured
Cross Reactions
Flow Cytometry
High-Throughput Screening Assays
Humans
Lymphocyte Activation
/ drug effects
Receptors, OX40
/ metabolism
Risk Assessment
T-Lymphocytes, Helper-Inducer
/ drug effects
Toxicity Tests
Tumor Necrosis Factor Receptor Superfamily, Member 9
/ metabolism
Up-Regulation
CD134
CD137
HLA II type
Immunogenicity
PMBC
T cell activation
T cell epitopes
anti-drug antibodies
biotherapeutics
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
5
11
2021
Statut:
ppublish
Résumé
Biotherapeutics, which are biologic medications that are natural or bioengineered products of living cells, have revolutionized the treatment of many diseases. However, unwanted immune responses still present a major challenge to their widespread adoption. Many patients treated with biotherapeutics develop antigen-specific anti-drug antibodies (ADAs) that may reduce the efficacy of the therapy or cross-react with the endogenous counterpart of a protein therapeutic, or both. Here, we describe an
Identifiants
pubmed: 33729092
doi: 10.1080/19420862.2021.1898831
pmc: PMC7993230
doi:
Substances chimiques
Antibodies, Monoclonal
0
Biological Products
0
Biomarkers
0
Receptors, OX40
0
TNFRSF4 protein, human
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1898831Références
Antibodies (Basel). 2018 May 31;7(2):
pubmed: 31544871
Expert Rev Proteomics. 2018 Sep;15(9):733-748
pubmed: 30198337
Trends Immunol. 2007 Nov;28(11):482-90
pubmed: 17964218
J Immunol Res. 2016;2016:8141269
pubmed: 27642612
Front Immunol. 2020 May 14;11:791
pubmed: 32477334
J Immunol. 2009 Aug 15;183(4):2827-36
pubmed: 19635903
Clin Cancer Res. 2003 Apr;9(4):1338-46
pubmed: 12684402
Eur J Immunol. 2020 Mar;50(3):445-458
pubmed: 31722123
PLoS One. 2017 May 31;12(5):e0178544
pubmed: 28562666
J Immunol. 1993 Feb 1;150(3):771-81
pubmed: 7678621
Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1116-21
pubmed: 15647361
J Pharm Sci. 2011 Feb;100(2):354-87
pubmed: 20740683
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Clin Cardiol. 2017 Jul;40(7):503-511
pubmed: 28326559
Dermatol Ther (Heidelb). 2018 Mar;8(1):57-68
pubmed: 29392570
J Immunol. 2000 Sep 15;165(6):3043-50
pubmed: 10975814
Bioanalysis. 2019 Dec;11(24):2283-2296
pubmed: 31845602
Eur J Immunol. 2002 Dec;32(12):3617-27
pubmed: 12516549
Immunology. 2000 Oct;101(2):169-77
pubmed: 11012769
J Exp Med. 2006 Jul 10;203(7):1693-700
pubmed: 16818676
J Immunotoxicol. 2019 Dec;16(1):125-132
pubmed: 31179789
J Immunol. 2011 Oct 1;187(7):3555-64
pubmed: 21880986
Clin Exp Immunol. 2012 Aug;169(2):137-47
pubmed: 22774988
Front Immunol. 2020 Jun 30;11:1301
pubmed: 32695107
J Immunotoxicol. 2014 Apr-Jun;11(2):99-109
pubmed: 23919460
Immunotherapy. 2019 Feb;11(3):241-254
pubmed: 30730275
N Engl J Med. 2017 Apr 20;376(16):1517-1526
pubmed: 28304227
PLoS One. 2016 Aug 05;11(8):e0159328
pubmed: 27494246
J Pharm Sci. 2019 May;108(5):1637-1654
pubmed: 30599169
Clin Diagn Lab Immunol. 2000 Jul;7(4):687-92
pubmed: 10882673
MAbs. 2020 Jan-Dec;12(1):1764829
pubmed: 32370596
Front Immunol. 2019 Dec 20;10:2894
pubmed: 31921155
J Exp Med. 1997 Jul 7;186(1):47-55
pubmed: 9206996
Springer Semin Immunopathol. 2001 Dec;23(4):405-19
pubmed: 11826617
FASEB J. 2011 Jun;25(6):2040-8
pubmed: 21368101
Eur J Pharm Biopharm. 2018 Sep;130:128-142
pubmed: 29894817
J Clin Pharmacol. 2014 Jan;54(1):14-22
pubmed: 23913720
J Pharm Pharmacol. 2018 May;70(5):584-594
pubmed: 28872677
AAPS J. 2020 Apr 16;22(3):68
pubmed: 32300899
BMC Pulm Med. 2019 Jan 7;19(1):5
pubmed: 30616547
AAPS J. 2019 Jul 24;21(5):94
pubmed: 31342199